Literature DB >> 19373528

Incidence and patterns of isolated brain failure in stage III non-small-cell lung cancer treated with concurrent chemoradiation therapy.

Yasushi Hamamoto1, Masaaki Kataoka, Takatoshi Senba, Kotaro Uwatsu, Shogo Oda, Tadaaki Takahashi, Shoji Aono, Shinya Sakai, Takeshi Inoue, Yoshifumi Sugawara.   

Abstract

PURPOSE: The incidence and patterns of isolated brain failure was examined in patients with stage III non-small-cell lung cancer (NSCLC) treated with concurrent chemoradiation (CCRT).
MATERIALS AND METHODS: Between 1996 and 2003, a total of 68 patients with stage III NSCLC were treated with radical CCRT. Among them, 63 patients were evaluable. Radiation therapy with a mean total dose of 61.4 Gy and chemotherapy (typically platinum-based) were administered concurrently.
RESULTS: Other than locoregional failure, isolated brain failure was the most common failure pattern as the initial failure, occurring 2-37 months (median 6.5 months) after radical CCRT. The isolated brain failure rates as the initial failure at 1, 3, and 4 years were 9%, 13%, and 25%, respectively. Isolated brain failure as the initial failure occurred more frequently in T4 cases (39% at 4 years) compared to T1-3 cases (14% at 4 years) in our series (P = 0.0099).
CONCLUSION: Except for locoregional failure, isolated brain failure was the most common initial failure pattern of stage III NSCLCs treated with radical CCRT. Isolated brain failure as the initial failure occurred even after 3 years. Isolated brain failure as the initial failure occurred more frequently in T4 cases than in T1-3 cases.

Entities:  

Mesh:

Year:  2009        PMID: 19373528     DOI: 10.1007/s11604-008-0292-1

Source DB:  PubMed          Journal:  Jpn J Radiol        ISSN: 1867-1071            Impact factor:   2.374


  17 in total

1.  Clinical predictors of metastatic disease to the brain from non-small cell lung carcinoma: primary tumor size, cell type, and lymph node metastases.

Authors:  Amol Mujoomdar; John H M Austin; Rohin Malhotra; Charles A Powell; Gregory D N Pearson; Maria C Shiau; Haralambos Raftopoulos
Journal:  Radiology       Date:  2007-01-17       Impact factor: 11.105

2.  Factors affecting the risk of brain metastases after definitive chemoradiation for locally advanced non-small-cell lung carcinoma.

Authors:  T J Robnett; M Machtay; J P Stevenson; K M Algazy; S M Hahn
Journal:  J Clin Oncol       Date:  2001-03-01       Impact factor: 44.544

3.  Patterns of relapse of N2 nonsmall-cell lung carcinoma patients treated with preoperative chemotherapy: should prophylactic cranial irradiation be reconsidered?

Authors:  F Andre; D Grunenwald; J L Pujol; P Girard; A Dujon; L Brouchet; P Y Brichon; V Westeel; T Le Chevalier
Journal:  Cancer       Date:  2001-06-15       Impact factor: 6.860

4.  Postoperative T1 N0 non-small cell lung cancer. Squamous versus nonsquamous recurrences. The Lung Cancer Study Group.

Authors: 
Journal:  J Thorac Cardiovasc Surg       Date:  1987-09       Impact factor: 5.209

5.  High risk of brain metastases in surgically staged IIIA non-small-cell lung cancer patients treated with surgery, chemotherapy, and radiation.

Authors:  Harvey J Mamon; Beow Yong Yeap; Pasi A Jänne; Jason Reblando; Sarah Shrager; Michael T Jaklitsch; Steven Mentzer; Jeanne M Lukanich; David J Sugarbaker; Elizabeth H Baldini; Stuart Berman; Arthur Skarin; Raphael Bueno
Journal:  J Clin Oncol       Date:  2005-03-01       Impact factor: 44.544

6.  Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.

Authors:  K Furuse; M Fukuoka; M Kawahara; H Nishikawa; Y Takada; S Kudoh; N Katagami; Y Ariyoshi
Journal:  J Clin Oncol       Date:  1999-09       Impact factor: 44.544

7.  Does the incidence and outcome of brain metastases in locally advanced non-small cell lung cancer justify prophylactic cranial irradiation or early detection?

Authors:  Hannah Carolan; Alexander Y Sun; Andrea Bezjak; Qi-Long Yi; David Payne; Gabrielle Kane; John Waldron; Natasha Leighl; Ronald Feld; Ronald Burkes; Shaf Keshavjee; Frances Shepherd
Journal:  Lung Cancer       Date:  2005-02-02       Impact factor: 5.705

8.  Role of elective brain irradiation during combined chemoradiotherapy for limited disease non-small cell lung cancer.

Authors:  T Umsawasdi; M Valdivieso; T T Chen; H T Barkley; D J Booser; D F Chiuten; H M Dhingra; W K Murphy; C L Dixon; P Farha
Journal:  J Neurooncol       Date:  1984       Impact factor: 4.130

9.  Prophylactic cranial irradiation for lung cancer patients at high risk for development of cerebral metastasis: results of a prospective randomized trial conducted by the Radiation Therapy Oncology Group.

Authors:  A H Russell; T E Pajak; H M Selim; J C Paradelo; K Murray; P Bansal; J D Cooper; S Silverman; J A Clement
Journal:  Int J Radiat Oncol Biol Phys       Date:  1991-08       Impact factor: 7.038

10.  Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study.

Authors:  Petr Zatloukal; Lubos Petruzelka; Milada Zemanova; Libor Havel; Filip Janku; Libor Judas; Antonin Kubik; Evzen Krepela; Pavel Fiala; Ladislav Pecen
Journal:  Lung Cancer       Date:  2004-10       Impact factor: 5.705

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.